Differences in sleep architecture according to body mass index in children with type 1 diabetes

2019 ◽  
Vol 21 (1) ◽  
pp. 98-105
Author(s):  
Salaheddin H. Elrokhsi ◽  
Grai P. Bluez ◽  
Cindy N. Chin ◽  
Mark D. Wheeler ◽  
Graciela E. Silva ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Type 1 Diabetes ◽  
Body Mass ◽  
Sleep Architecture

Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme

2020 ◽  
Vol 22 (5) ◽  
pp. 857-865
Author(s):  
Jason Gordon ◽  
Lee Beresford‐Hulme ◽  
Hayley Bennett ◽  
Amarjeet Tank ◽  
Christopher Edmonds ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trial ◽  
Body Mass Index ◽  
Type 1 Diabetes ◽  
Body Mass ◽  
Clinical Trial Programme

scholarly journals Effects of Metformin Added to Insulin in Adolescents with Type 1 Diabetes: An Exploratory Crossover Randomized Trial

2020 ◽  
Vol 2020 ◽  
pp. 1-10
Author(s):  
Daizhi Yang ◽  
Jinhua Yan ◽  
Hongrong Deng ◽  
Xubin Yang ◽  
Sihui Luo ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Heart Rate ◽  
Heart Rate Variability ◽  
Type 1 Diabetes ◽  
Insulin Sensitivity ◽  
Body Mass ◽  
Autonomic Function ◽  
Insulin Dose ◽  
Glucose Variability

Background. To comprehensively assess the effects of metformin added to insulin on metabolic control, insulin sensitivity, and cardiovascular autonomic function in adolescents with type 1 diabetes. Materials and Methods. This was an exploratory, crossover, randomized trial conducted in adolescents with type 1 diabetes aged 12-18 years old. Participants were randomly received metformin (≤1000 mg/d) added to insulin for 24 weeks followed by insulin monotherapy for a subsequent 24 weeks or vice versa. Blood pressure, body mass index, insulin dose, estimated insulin sensitivity, glycated hemoglobin A1c (HbA1c), and lipid profiles were measured, with a 72-hour continuous glucose monitoring and 24-hour Holter monitoring performed at baseline, 24, and 50 weeks for the assessments of glucose variability and heart rate variability. Results. Seventeen patients with mean ± SD age 14.4 ± 2.3   years , body mass index 18.17 ± 1.81   kg / m 2 , median (IQR) diabetes duration 4.50 (3.58, 6.92) years, and HbA1c 9.0% (8.5%, 9.4%) were enrolled. The between-group difference in HbA1c of 0.28% (95% CI -0.39 to 0.95%) was not significant ( P = 0.40 ). Changes in body mass index, insulin dose, blood pressure, lipid profiles, and estimated insulin sensitivity were similar for metformin add-on vs. insulin monotherapy. Glucose variability also did not differ. Compared with insulin monotherapy, metformin add-on significantly increased multiple heart rate variability parameters. Conclusions. Metformin added to insulin did not improve metabolic control or glucose variability in lean/normal-weight adolescents with type 1 diabetes. However, metformin added to insulin significantly increased heart rate variability, suggesting that metformin might improve cardiovascular autonomic function in this population.

Allergic sensitization and symptoms, body mass index, and respiratory function in children with type 1 diabetes mellitus

2012 ◽  
Vol 108 (2) ◽  
pp. 128-129 ◽  
Author(s):  
Maria Angela Tosca ◽  
Michela Silvestri ◽  
Roberta Olcese ◽  
Giuseppe D'Annunzio ◽  
Angela Pistorio ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Body Mass ◽  
Respiratory Function ◽  
Allergic Sensitization

Is the change in body mass index among children newly diagnosed with type 1 diabetes mellitus associated with obesity at transition from pediatric to adult care?

2016 ◽  
Vol 17 (8) ◽  
pp. 599-607 ◽  
Author(s):  
Taru Manyanga ◽  
Elizabeth AC Sellers ◽  
Brandy A Wicklow ◽  
Malcolm Doupe ◽  
Randall Fransoo
Keyword(s):  
Diabetes Mellitus ◽  
Body Mass Index ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Body Mass ◽  
Newly Diagnosed ◽  
Adult Care
Sign in / Sign up

Export Citation Format

Share Document